 NEW YORK, Oct. 07, 2021 GLOBE NEWSWIRE -- Ovid Therapeutics Inc. NASDAQ: OVID, a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has appointed Kevin Fitzgerald, Ph.D., to its Board of Directors. 